DOCSLIB.ORG

Newer and Common Inhaled Therapy Licensed for Asthma Or Copd February 2021

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Newer and Common Inhaled Therapy Licensed for Asthma Or Copd February 2021 NEWER AND COMMON INHALED THERAPY LICENSED FOR ASTHMA OR COPD FEBRUARY 2021 DEVICE SABA SAMA LAMA LABA ICS generic (Trade) short acting B2 short acting long acting muscarinic antagonist long acting B2 agonist inhaled glucoccortico steroid agonist muscarinic antagonist Metered dose inhaler salbutamol ipratropium formoterol fluticasone & salmeterol beclometasone (Aspire, AstraZeneca, (Ventolin®, (Atrovent®) (Atimos®) (AirFluSal®*, Aloflute®*, (Qvar®, Clenil®, Chiesi, Cipla, Fannin, Airomir®) Combisal®*, Sereflo®*, Seretide®, Kelhale®*, Glenmark GSK, Mylan, salmeterol Sirdupla®*) Soprobec®*) Napp, Teva, Kent) (Neovent®, budesonide & formoterol fluticasone Serevent®, (Symbicort®**) (Flixotide®*) Solotel®) beclometasone & formoterol ciclesonide (Fostair®) (Alvesco®*) fluticasone & formoterol (Flutiform®*) glycopyrronium & formoterol (Bevespi Aerosphere®**) glycopyrronium, formoterol, beclometasone (Trimbow®) glycopyrronium, formoterol, budesonide (Trixeo Aerosphere®**) Easibreathe salbutamol beclometasone (Teva) (Salamol®) (Qvar®) Autohaler salbutamol beclometasone (Teva) (Airomir®) (Qvar®) K-haler fluticasone & formoterol (Napp) (Flutiform®*) Respimat tiotropium tiotropium & olodaterol olodaterol (Boehringer) (Spiriva®) (Spiolto®**) (Striverdi®**) HandiHaler tiotropium** (Boehringer) (Spiriva®) Easyhaler Easyhaler® Easyhaler® Easyhaler® beclometasone* (Orion) salbutamol formoterol Easyhaler® budesonide* formoterol & budesonide (Fobumix®***) salmeterol & fluticasone (Fusacomb®) Turbohaler terbutaline formoterol formoterol & budesonide budesonide (AstraZeneca) (Bricanyl®) (Oxis®) (Symbicort®)*** (Pulmicort®) Accuhaler salbutamol salmeterol salmeterol & fluticasone fluticasone (GlaxoSmithKlein) (Ventolin®) (Serevent®) (Seretide®) (Flixotide®) Nexthaler formoterol & beclometasone (Chiesi (Fostair®***) NEWER AND COMMON INHALED THERAPY LICENSED FOR ASTHMA OR COPD FEBRUARY 2021 DEVICE SABA SAMA LAMA LABA ICS generic (Trade) short acting B2 short acting long acting muscarinic antagonist long acting B2 agonist inhaled glucoccortico steroid agonist muscarinic antagonist Breezhaler glycopyrronium glycopyrronium & indacaterol indacaterol (Novartis) (Seebri®**) (Ultibro®**) (Onbrez®**) indacaterol & mometasone (Atectura®*) glycopyrronium, indacaterol, mometasone (Enerzair®*) Genuair aclidinium aclidinium & formoterol (AstraZeneca) (Eklira®**) (Duaklir®**) Ellipta umeclidinium umeclidinium & vilanterol fluticasone furoate & vilanterol (GlaxoSmithKlein) (Incruse®**) (Anoro®**) (Relvar®) umeclidinium, vilanterol, fluticasone (Trelegy®**) Spiromax formoterol & budesonide (Teva) (DuoResp®***) salmeterol & fluticasone (Aerivio®) Forspiro salmeterol & fluticasone (Sandoz) (AirFluSal®) Zonda tiotropium** (Teva) Braltus® Twisthaler mometasone (MSD) (Asmanex®*) Novoliser salbutamol budesonide (Meda) (Salbulin®) (Budelin®*) Aeroliser formoterol (Novartis) (Foradil®) Stalpex fluticasone & salmeterol (Glenmark) (Stalpex®) Source: Electronic Medicines Compendium UK 2021; MIMS.co.uk 2021. See Summary of Product Characteristics for full indications and prescribing information. Check your local formulary for specific advice in your area. New for 2021: Enerzair (LABA/LAMA/ICS) and Atectura (ICS/LABA) for asthma. licensed for asthma (in addition to COPD). Bevespi (LABA/LAMA) and Trixeo (LABA/LAMA/ICS) for COPD. Sodium cromoglicate (Intal®) and nedocromil sodium (Tilade®) also available in MDI. *Licensed for asthma only **Licensed for COPD only ***Licensed for Maintenance And Reliever Therapy (MART) in asthma Produced by Andrew Booth for the Primary Care Training Centre. www.primarycaretraining.co.uk and the Association of Respiratory Nurse Specialists. www.arns.co.uk.
Load more

Recommended publications
  • (CD-P-PH/PHO) Report Classification/Justifica
    COMMITTEE OF EXPERTS ON THE CLASSIFICATION OF MEDICINES AS REGARDS THEIR SUPPLY (CD-P-PH/PHO) Report classification/justification of medicines belonging to the ATC group R01 (Nasal preparations) Table of Contents Page INTRODUCTION 5 DISCLAIMER 7 GLOSSARY OF TERMS USED IN THIS DOCUMENT 8 ACTIVE SUBSTANCES Cyclopentamine (ATC: R01AA02) 10 Ephedrine (ATC: R01AA03) 11 Phenylephrine (ATC: R01AA04) 14 Oxymetazoline (ATC: R01AA05) 16 Tetryzoline (ATC: R01AA06) 19 Xylometazoline (ATC: R01AA07) 20 Naphazoline (ATC: R01AA08) 23 Tramazoline (ATC: R01AA09) 26 Metizoline (ATC: R01AA10) 29 Tuaminoheptane (ATC: R01AA11) 30 Fenoxazoline (ATC: R01AA12) 31 Tymazoline (ATC: R01AA13) 32 Epinephrine (ATC: R01AA14) 33 Indanazoline (ATC: R01AA15) 34 Phenylephrine (ATC: R01AB01) 35 Naphazoline (ATC: R01AB02) 37 Tetryzoline (ATC: R01AB03) 39 Ephedrine (ATC: R01AB05) 40 Xylometazoline (ATC: R01AB06) 41 Oxymetazoline (ATC: R01AB07) 45 Tuaminoheptane (ATC: R01AB08) 46 Cromoglicic Acid (ATC: R01AC01) 49 2 Levocabastine (ATC: R01AC02) 51 Azelastine (ATC: R01AC03) 53 Antazoline (ATC: R01AC04) 56 Spaglumic Acid (ATC: R01AC05) 57 Thonzylamine (ATC: R01AC06) 58 Nedocromil (ATC: R01AC07) 59 Olopatadine (ATC: R01AC08) 60 Cromoglicic Acid, Combinations (ATC: R01AC51) 61 Beclometasone (ATC: R01AD01) 62 Prednisolone (ATC: R01AD02) 66 Dexamethasone (ATC: R01AD03) 67 Flunisolide (ATC: R01AD04) 68 Budesonide (ATC: R01AD05) 69 Betamethasone (ATC: R01AD06) 72 Tixocortol (ATC: R01AD07) 73 Fluticasone (ATC: R01AD08) 74 Mometasone (ATC: R01AD09) 78 Triamcinolone (ATC: R01AD11) 82
    [Show full text]
  • Composition for Rectal Administration Combined with an Oral Alpha-Lipoic
    (19) & (11) EP 2 162 125 B1 (12) EUROPEAN PATENT SPECIFICATION (45) Date of publication and mention (51) Int Cl.: of the grant of the patent: A61K 31/136 (2006.01) A61K 31/01 (2006.01) 19.10.2011 Bulletin 2011/42 A61P 1/00 (2006.01) A61K 45/06 (2006.01) A61K 31/56 (2006.01) A61K 31/573 (2006.01) (2006.01) (21) Application number: 08768441.1 A61K 31/606 (22) Date of filing: 13.06.2008 (86) International application number: PCT/US2008/007401 (87) International publication number: WO 2008/156671 (24.12.2008 Gazette 2008/52) (54) Composition for rectal administration combined with an oral alpha-lipoic acid composition for the treatment of inflammatory bowel disease Zusammensetzung zur rektalen Verabreichung kombiniert mit einer oralen Zusammentzung enthaltend alpha Liponsäure zur Behandlung von entzündlicher Darmerkrankung Composition pour l’administration rectale en combinaison avec une composition orale de l’ acide alpha- lipoique pour le traitment des maladies intestinales inflammatoires (84) Designated Contracting States: (56) References cited: AT BE BG CH CY CZ DE DK EE ES FI FR GB GR EP-B1- 0 671 168 WO-A2-02/089796 HR HU IE IS IT LI LT LU LV MC MT NL NO PL PT US-A- 4 657 900 US-A- 5 082 651 RO SE SI SK TR US-A- 5 378 470 (30) Priority: 13.06.2007 US 934505 P • MULDER CJ. ET AL.: ’Beclomethasone 06.02.2008 US 63745 P dipropionate (3mg) versus 5- aminosalicylic acid (2g) versus the combination of both (3mg/2g)as (43) Date of publication of application: retention enemas in active ulcerative proctitis’ 17.03.2010 Bulletin 2010/11 EUR.J.GASTROENTEROL HEPATOL vol.
    [Show full text]
  • Difference Between Patient-Reported Side Effects of Ciclesonide Versus fluticasone Propionate
    View metadata, citation and similar papers at core.ac.uk brought to you by CORE provided by Elsevier - Publisher Connector Respiratory Medicine (2010) 104, 1825e1833 available at www.sciencedirect.com journal homepage: www.elsevier.com/locate/rmed Difference between patient-reported side effects of ciclesonide versus fluticasone propionate Thys van der Molen a, Juliet M. Foster a,b, Manfred Caeser c,e, Thomas Mu¨ller c, Dirkje S. Postma d,* a Department of General Practice, University Medical Center Groningen, University of Groningen, Hanzeplein 1, 9700 RB, Groningen, The Netherlands b Woolcock Institute of Medical Research, 431 Glebe Point Rd, Glebe NSW 2037, Sydney, Australia c Nycomed GmbH, Byk-Gulden-Straße 2, 78467 Konstanz, Konstanz, Germany d Department of Pulmonary Diseases, University Medical Center Groningen, University of Groningen, Hanzeplein 1, 9700 RB, Groningen, The Netherlands Received 18 January 2010; accepted 26 May 2010 Available online 2 July 2010 KEYWORDS Summary Adverse events; Rationale: Patient-reported outcomes provide new insights into the dynamics of asthma Inhaled corticosteroid management. Further to asthma control and quality of life, self-reported side effects of treat- questionnaire; ment can be assessed with the validated Inhaled Corticosteroid Questionnaire (ICQ). ICQ; Objectives: To compare patient-reported side effects between the inhaled corticosteroids Patient-reported ciclesonide and fluticasone propionate. outcomes Methods: Patients with moderate or moderate-to-severe asthma, pre-treated with a constant dose and type of medication, were randomized in three separate studies: 1) once daily cicle- sonide 320 mg(n Z 234) or twice daily fluticasone propionate 200 mg(n Z 240); 2) twice daily ciclesonide 320 mg(n Z 255) or twice daily fluticasone propionate 375 mg(n Z 273); and 3) twice daily ciclesonide 320 mg(n Z 259) or twice daily fluticasone propionate 500 mg (n Z 244).
    [Show full text]
  • Inhaled Corticosteroid (ICS) Only – Metered Dose Inhalers (MDI)
    Categorisation and Formulary Choices of Inhaled Corticosteroids for Adults Inhaled Corticosteroid (ICS) only – Metered Dose Inhalers (MDI) MDI Beclometasone dipropionate Use with a compatible Fluticasone Propionate spacer device Prescribe by BRAND Clenil Modulite® Qvar®(extrafine) Qvar®(extrafine) Flixotide® Evohaler MDI Easi-Breathe Low Dose 100mcg, two puffs twice a 50 mcg, two puffs twice a day 50 mcg, two puffs twice a day 50 mcg, two puffs twice a day (BDP equivalent day (200 dose) (200 dose) (200 dose) (120 dose) ≤400mcg BDP) £4.45/month £4.72/month £4.64/month £5.44/month Medium Dose 200mcg, two puffs twice a 100 mcg, two puffs twice a day 100 mcg, two puffs twice a day 125mcg, two puffs twice a day (BDP equivalent day (200 dose) (200 dose) (200 dose) (120 dose) 400-1000mcg BDP) £9.70/month £10.33/month £10.17/month £12.50/month High Dose 250mcg, two puffs twice a 100 mcg, four puffs twice a day 100 mcg, four puffs twice a day 250mcg, two puffs twice a day (BDP equivalent day (200 dose) (200 dose) (200 dose) (120 dose) >1000mcg BDP) £9.77/month £20.66/month £20.34/month £20.00/month Simultaneous specialist OR referral recommended 250mcg four puffs, twice a day (200 dose) £19.55/month Prices correct as per Drug Tariff and DM&D December2018 1st line choices (dark green, solid border) 2nd line choices (light green, dashed border) Approved by Hertfordshire Medicines Management Committee – October 2018 Inhaled Corticosteroid (ICS) only – Dry Powder Inhalers (DPI) Beclometasone DPI dipropionate Budesonide Fluticasone Propionate Prescribe
    [Show full text]
  • The Inhaled Steroid Ciclesonide Blocks SARS-Cov-2 RNA Replication by Targeting Viral
    bioRxiv preprint doi: https://doi.org/10.1101/2020.08.22.258459; this version posted August 24, 2020. The copyright holder for this preprint (which was not certified by peer review) is the author/funder. All rights reserved. No reuse allowed without permission. 1 The inhaled steroid ciclesonide blocks SARS-CoV-2 RNA replication by targeting viral 2 replication-transcription complex in culture cells 3 4 Shutoku Matsuyamaa#, Miyuki Kawasea, Naganori Naoa, Kazuya Shiratoa, Makoto Ujikeb, Wataru 5 Kamitanic, Masayuki Shimojimad, and Shuetsu Fukushid 6 7 aDepartment of Virology III, National Institute of Infectious Diseases, Tokyo, Japan 8 bFaculty of Veterinary Medicine, Nippon Veterinary and Life Science University, Tokyo, Japan 9 cDepartment of Infectious Diseases and Host Defense, Gunma University Graduate School of 10 Medicine, Gunma, Japan 11 dDepartment of Virology I, National Institute of Infectious Diseases, Tokyo, Japan. 12 13 Running Head: Ciclesonide blocks SARS-CoV-2 replication 14 15 #Address correspondence to Shutoku Matsuyama, [email protected] 16 17 Word count: Abstract 149, Text 3,016 bioRxiv preprint doi: https://doi.org/10.1101/2020.08.22.258459; this version posted August 24, 2020. The copyright holder for this preprint (which was not certified by peer review) is the author/funder. All rights reserved. No reuse allowed without permission. 18 Abstract 19 We screened steroid compounds to obtain a drug expected to block host inflammatory responses and 20 MERS-CoV replication. Ciclesonide, an inhaled corticosteroid, suppressed replication of MERS-CoV 21 and other coronaviruses, including SARS-CoV-2, the cause of COVID-19, in cultured cells. The 22 effective concentration (EC90) of ciclesonide for SARS-CoV-2 in differentiated human bronchial 23 tracheal epithelial cells was 0.55 μM.
    [Show full text]
  • Etats Rapides
    List of European Pharmacopoeia Reference Standards Effective from 2015/12/24 Order Reference Standard Batch n° Quantity Sale Information Monograph Leaflet Storage Price Code per vial Unit Y0001756 Exemestane for system suitability 1 10 mg 1 2766 Yes +5°C ± 3°C 79 ! Y0001561 Abacavir sulfate 1 20 mg 1 2589 Yes +5°C ± 3°C 79 ! Y0001552 Abacavir for peak identification 1 10 mg 1 2589 Yes +5°C ± 3°C 79 ! Y0001551 Abacavir for system suitability 1 10 mg 1 2589 Yes +5°C ± 3°C 79 ! Y0000055 Acamprosate calcium - reference spectrum 1 n/a 1 1585 79 ! Y0000116 Acamprosate impurity A 1 50 mg 1 3-aminopropane-1-sulphonic acid 1585 Yes +5°C ± 3°C 79 ! Y0000500 Acarbose 3 100 mg 1 See leaflet ; Batch 2 is valid until 31 August 2015 2089 Yes +5°C ± 3°C 79 ! Y0000354 Acarbose for identification 1 10 mg 1 2089 Yes +5°C ± 3°C 79 ! Y0000427 Acarbose for peak identification 3 20 mg 1 Batch 2 is valid until 31 January 2015 2089 Yes +5°C ± 3°C 79 ! A0040000 Acebutolol hydrochloride 1 50 mg 1 0871 Yes +5°C ± 3°C 79 ! Y0000359 Acebutolol impurity B 2 10 mg 1 -[3-acetyl-4-[(2RS)-2-hydroxy-3-[(1-methylethyl)amino] propoxy]phenyl] 0871 Yes +5°C ± 3°C 79 ! acetamide (diacetolol) Y0000127 Acebutolol impurity C 1 20 mg 1 N-(3-acetyl-4-hydroxyphenyl)butanamide 0871 Yes +5°C ± 3°C 79 ! Y0000128 Acebutolol impurity I 2 0.004 mg 1 N-[3-acetyl-4-[(2RS)-3-(ethylamino)-2-hydroxypropoxy]phenyl] 0871 Yes +5°C ± 3°C 79 ! butanamide Y0000056 Aceclofenac - reference spectrum 1 n/a 1 1281 79 ! Y0000085 Aceclofenac impurity F 2 15 mg 1 benzyl[[[2-[(2,6-dichlorophenyl)amino]phenyl]acetyl]oxy]acetate
    [Show full text]
  • Ep 2626065 A1
    (19) TZZ Z_T (11) EP 2 626 065 A1 (12) EUROPEAN PATENT APPLICATION published in accordance with Art. 153(4) EPC (43) Date of publication: (51) Int Cl.: A61K 31/137 (2006.01) A61K 31/135 (2006.01) 14.08.2013 Bulletin 2013/33 A61K 31/4704 (2006.01) A61K 31/58 (2006.01) A61K 31/56 (2006.01) A61K 9/12 (2006.01) (2006.01) (2006.01) (21) Application number: 11827927.2 A61K 9/14 A61P 11/06 (86) International application number: Date of filing: 01.02.2011 (22) PCT/CN2011/070883 (87) International publication number: WO 2012/041031 (05.04.2012 Gazette 2012/14) (84) Designated Contracting States: (72) Inventor: WU, Wei-hsiu AL AT BE BG CH CY CZ DE DK EE ES FI FR GB Taipei GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO Taiwan (TW) PL PT RO RS SE SI SK SM TR (74) Representative: Patentanwaltskanzlei WILHELM (30) Priority: 28.09.2010 CN 201010502339 & BECK Prinzenstrasse 13 (71) Applicant: Intech Biopharm Ltd. 80639 München (DE) Taipei (TW) (54) COMPOUND COMPOSITION FOR INHALATION USED FOR TREATING ASTHMA (57) An inhaled pharmaceutical composition con- tric way as a controller. The eccentric way control therapy tains primary active ingredients of beta2- agonist and cor- could create a low blood concentration period during the ticosteroids.The pharmaceuticalcompositions disclosed day and minimize the acute tolerance phenomenon (or in the present invention are to be inhaled by a patient so called tachyphylaxis) for bronchodilator - beta2-ago- when needed as a reliever, or administrated in an eccen- nists in treating asthma or other obstructive respiratory disorders.
    [Show full text]
  • Long-Acting Fixed-Dose Combination Products for Asthma/COPD SPECIAL AUTHORIZATION REQUEST FORM
    Long-Acting Fixed-Dose Combination Products for Asthma/COPD SPECIAL AUTHORIZATION REQUEST FORM Patients may or may not meet eligibility requirements as established by Please complete all required sections to allow your request to be processed Alberta government-sponsored drug programs PATIENT INFORMATION COVERAGE TYPE PATIENT LAST NAME FIRST NAME INITIAL Alberta Blue Cross Alberta Human Services BIRTHDATE (YYYY-MM-DD) ALBERTA PERSONAL HEALTH NUMBER Other STREET ADDRESS CITY PROV POSTAL CODE ID/CLIENT/COVERAGE NUMBER PRESCRIBER INFORMATION PRESCRIBER LAST NAME FIRST NAME INITIAL PRESCRIBER PROFESSIONAL ASSOCIATION REGISTRATION CPSA ACO REGISTRATION NUMBER STREET ADDRESS CARNA ADA+C ACP Other CITY , PROVINCE PHONE FAX POSTAL CODE FAX NUMBER MUST BE PROVIDED WITH EACH REQUEST SUBMITTED Please select requested drug (and specific strength or product, where applicable) Complete the following section(s) Budesonide + formoterol fumarate dihydrate (such as Symbicort) Fluticasone furoate + vilanterol trifenatate (such as Breo Ellipta) Applicable strength 100 mcg/25 mcg Section I and/or II Fluticasone propionate + salmeterol xinafoate (such as Advair) Applicable products 250 mcg/50 mcg inhalation powder 500 mcg/50 mcg inhalation powder Fluticasone furoate + vilanterol trifenatate (such as Breo Ellipta) Applicable strength 200 mcg/25 mcg Section I only Fluticasone propionate + salmeterol xinafoate (such as Advair) Applicable products 100 mcg/50 mcg inhalation powder Advair 125 MDI Advair 250 MDI Aclidinium bromide + formoterol fumarate dihydrate (such as Duaklir Genuair) Fluticasone furoate + umeclidinium bromide + vilanterol trifenatate (such as Trelegy Ellipta) Glycopyrronium bromide + indacaterol maleate (such as Ultibro Breezhaler) Section II only Tiotropium bromide + olodaterol hydrochloride (such as Inspiolto Respimat) Umeclidinium bromide + vilanterol trifenatate (such as Anoro Ellipta) Section I.
    [Show full text]
  • BSG Plan for IBD Patients During COVID19 Pandemic V1.5 349.88 KB
    British Society of Gastroenterology (BSG) advice for management of inflammatory bowel diseases during the COVID-19 pandemic Date of publication: 22nd March 2020 Introduction Inflammatory bowel disease (IBD), comprising Crohn’s disease (CD) and ulcerative colitis (UC), is a condition in which the gastrointestinal immune system responds inappropriately. It is therefore often treated with immune suppression medications to control inflammation and to prevent ‘flares’, a worsening in symptoms, which may be unpredictable. It is known that 0.8% of people in the UK (approx. 524,000 patients) currently have IBD, but only 44% have been to a clinic in the last 3 years1,2. There will be many patients who will be worried about the effect of the Coronavirus pandemic (SARS-CoV-2 or COVID-19 disease) on their IBD and vice versa. During the COVID-19 outbreak we will do everything we can to keep our IBD patients safe. The biggest risks are related not only to the infection itself, but also the emergency reorganisation of hospital and general practice services to deal with the pandemic, meaning routine IBD services will be significantly affected. A combined approach covering both primary and secondary care is therefore required to keep vulnerable IBD patients out of hospital as much as possible. Insights from Hubei, China and from Italy suggest hospital admission for non-COVID-19 illness will provide a reservoir for further spread of infection. However, alterations to the way we deliver IBD care in the UK must be balanced against the risks of undertreated, active IBD. Importantly, patients with active IBD are likely to have a higher risk of infection both in the community and during inpatient care, even in the absence of immunosupressant treatment3.
    [Show full text]
  • FF/UMEC/VI) Triple Therapy Versus Tiotropium Monotherapy in Patients with COPD
    www.nature.com/npjpcrm ARTICLE OPEN Single-inhaler fluticasone furoate/umeclidinium/vilanterol (FF/UMEC/VI) triple therapy versus tiotropium monotherapy in patients with COPD Sandeep Bansal1, Martin Anderson2, Antonio Anzueto3,4, Nicola Brown5, Chris Compton6, Thomas C. Corbridge7,8, David Erb9, Catherine Harvey5, Morrys C. Kaisermann10, Mitchell Kaye11, David A. Lipson 10,12, Neil Martin6,13, Chang-Qing Zhu5 and ✉ Alberto Papi 14 Chronic obstructive pulmonary disease (COPD) treatment guidelines do not currently include recommendations for escalation directly from monotherapy to triple therapy. This 12-week, double-blind, double-dummy study randomized 800 symptomatic moderate-to-very-severe COPD patients receiving tiotropium (TIO) for ≥3 months to once-daily fluticasone furoate/umeclidinium/ vilanterol (FF/UMEC/VI) 100/62.5/25 mcg via ELLIPTA (n = 400) or TIO 18 mcg via HandiHaler (n = 400) plus matched placebo. Study endpoints included change from baseline in trough forced expiratory volume in 1 s (FEV1) at Days 85 (primary), 28 and 84 (secondary), health status (St George’s Respiratory Questionnaire [SGRQ] and COPD Assessment Test [CAT]) and safety. FF/UMEC/VI significantly improved trough FEV1 at all timepoints (Day 85 treatment difference [95% CI] 95 mL [62–128]; P < 0.001), and significantly improved SGRQ and CAT versus TIO. Treatment safety profiles were similar. Once-daily single-inhaler FF/UMEC/VI significantly improved lung function and health status versus once-daily TIO in symptomatic moderate-to-very-severe COPD 1234567890():,; patients, with a similar safety profile. npj Primary Care Respiratory Medicine (2021) 31:29 ; https://doi.org/10.1038/s41533-021-00241-z INTRODUCTION performed to date and a lack of updated recommendations Chronic obstructive pulmonary disease (COPD) is a major cause of based on the current body of evidence.
    [Show full text]
  • A Practical Approach To, Diagnosis, Assessment and Management Of
    REVIEW A practical approach to, diagnosis, Pract Neurol: first published as 10.1136/practneurol-2014-000821 on 8 May 2014. Downloaded from assessment and management of idiopathic intracranial hypertension Susan P Mollan,1 Keira A Markey,2 James D Benzimra,1 Andrew Jacks,1 Tim D Matthews,1 Michael A Burdon,1 Alex J Sinclair2,3 1Birmingham Neuro- ABSTRACT term to encompass primary raised intra- Ophthalmology Unit, Adult patients who present with papilloedema cranial pressure where there is no identi- Ophthalmology Department, — — University Hospitals Birmingham and symptoms of raised intracranial pressure fiable cause which we term IIH and 3 NHS Trust, Queen Elizabeth need urgent multidisciplinary assessment secondary causes of raised pressure. Hospital Birmingham, including neuroimaging, to exclude life- The diagnostic criteria of IIH are well Birmingham, UK 2 threatening causes. Where there is no apparent known and have evolved since Dandy’s Neurotrauma and 4 Neurodegeneration, School of underlying cause for the raised intracranial initial description in 1937 ; they include Clinical and Experimental pressure, patients are considered to have a CSF opening pressure of ≥25 cm H2O Medicine, College of Medical idiopathic intracranial hypertension (IIH). The (box 1).3 However, these criteria recom- and Dental Sciences, The incidence of IIH is increasing in line with the mend imaging only to exclude a venous Medical School, The University of Birmingham, Birmingham, UK global epidemic of obesity. There are sinus thrombosis in patients without the 3Department of Neurology, controversial issues in its diagnosis and typical IIH phenotype (obesity and University Hospital Birmingham management. This paper gives a practical female sex). We feel, however, that it is NHS Trust, Queen Elizabeth Hospital Birmingham, approach to assessing patients with essential to exclude venous sinus throm- Birmingham, UK papilloedema, its investigation and the bosis (using MRI or CT with venography) subsequent management of patients with IIH.
    [Show full text]
  • Utah Medicaid Pharmacy and Therapeutics Committee Drug
    Utah Medicaid Pharmacy and Therapeutics Committee Drug Class Review Single Ingredient Nasal Corticosteroids Beclomethasone dipropionate (Qnasl) Beclomethasone dipropionate monohydrate (Beconase AQ) Budesonide (Rhinocort) Ciclesonide (Omnaris, Zetonna) Flunisolide (Generic) Fluticasone Furoate (Flonase Sensimist) Fluticasone Propionate (Flonase, Xhance) Mometasone Furoate (Nasonex) Triamcinolone Acetonide (Nasacort) AHFS Classification: 52.08.08 Corticosteroids (EENT) Final Report February 2018 Review prepared by: Valerie Gonzales, Pharm.D., Clinical Pharmacist Elena Martinez Alonso, B.Pharm., MSc MTSI, Medical Writer Vicki Frydrych, Pharm.D., Clinical Pharmacist Joanita Lake, B.Pharm., MSc EBHC (Oxon), Research Assistant Professor Joanne LaFleur, Pharm.D., MSPH, Associate Professor University of Utah College of Pharmacy University of Utah College of Pharmacy, Drug Regimen Review Center Copyright © 2018 by University of Utah College of Pharmacy Salt Lake City, Utah. All rights reserved Contents Abbreviations ................................................................................................................................................ 2 Executive Summary ....................................................................................................................................... 3 Introduction .................................................................................................................................................. 5 Table 1. Nasal corticosteroid products .............................................................................................
    [Show full text]